Neurocrine

$116.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.91 (+1.66%) Today

$0.00 (0.00%) As of 10:47 AM UTC after-hours

Why Robinhood?

You can buy or sell Neurocrine and other stocks, options, and ETFs commission-free!

About NBIX

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA. The listed name for NBIX is Neurocrine Biosciences, Inc. Common Stock.

CEO

Kevin Charles Gorman

Employees

700

Headquarters

San Diego, California

Founded

1992

Market Cap

10.55B

Price-Earnings Ratio

125.90

Dividend Yield

—

Average Volume

1.20M

High Today

$117.71

Low Today

$114.09

Open Price

$115.33

Volume

647.92K

52 Week High

$136.27

52 Week Low

$72.14

Collections

NBIX News

BenzingaJan 20

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report fourth quarter and year-end 2020 financi

Analyst Ratings

64%

of 25 ratings

Buy

64%

Hold

36%

Sell

NBIX Earnings

$0.00

$0.47

$0.95

$1.42

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Available Feb 4, After Hours